Complement and Cancer In 2007, the first truly complement-targeted drug, the anti-C5 monoclonal antibody eculizumab (Eculizumab, Soliris), was approved for the treatment of PNH, and has achieved a revolutionary success, not onlyRead More…

The complement system has long been recognized as a central player in innate immunity, defending the host against infections while maintaining tissue homeostasis. Among its components, complement C3 stands as a pivotalRead More…